The biology of chronic myelogenous leukemia: implications for imatinib therapy
RH Alvarez, H Kantarjian, JE Cortes - Seminars in hematology, 2007 - Elsevier
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of primitive
hematopoietic stem cells, and has been classified as a myeloproliferative disorder. The …
hematopoietic stem cells, and has been classified as a myeloproliferative disorder. The …
BCR–ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring
MH Luu, RD Press - Expert Review of Molecular Diagnostics, 2013 - Taylor & Francis
The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML)
represents the paradigm for modern targeted cancer therapy. Importantly, molecular …
represents the paradigm for modern targeted cancer therapy. Importantly, molecular …
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
patients with chronic myelogenous leukemia. Many mutations favor active kinase …
Physical therapy utilization among hospitalized patients with pediatric acute lymphoblastic leukemia
RL Rodwin, X Ma, KK Ness, NS Kadan-Lottick… - JCO Oncology …, 2022 - ascopubs.org
PURPOSE: Patients with pediatric acute lymphoblastic leukemia (ALL) are at risk for
impaired physical function from treatment. Early physical therapy (PT) may improve physical …
impaired physical function from treatment. Early physical therapy (PT) may improve physical …
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns
HM Kantarjian, J Cortes, F Guilhot… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND. The success of imatinib therapy for chronic myeloid leukemia (CML) has
brought new challenges; these include optimizing disease monitoring, imatinib resistance …
brought new challenges; these include optimizing disease monitoring, imatinib resistance …
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period
U Bacher, AR Zander, T Haferlach… - Bone marrow …, 2008 - nature.com
Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic
myeloproliferative diseases (CMPDs) and in poor-risk AML. Techniques to monitor the …
myeloproliferative diseases (CMPDs) and in poor-risk AML. Techniques to monitor the …
[HTML][HTML] Precision Isolation of Circulating Leukemia Cells in Chronic Myelogenous Leukemia Patients Using a Novel Microfluidic Device and Its Clinical Applications
D Ouyang, N Ye, K Yang, Y Wang, L Hu, S Chao… - Cancers, 2023 - mdpi.com
Simple Summary Chronic Myelogenous Leukemia (CML) is a common blood cancer that
involves the uncontrolled growth of certain blood cells. Treating this disease effectively …
involves the uncontrolled growth of certain blood cells. Treating this disease effectively …
Magnetic Nanoparticles PCR Enzyme‐Linked Gene Assay for Quantitative Detection of BCR/ABL Fusion Gene in Chronic Myelogenous Leukemia
Y Manthawornsiri, D Polpanich… - Journal of Clinical …, 2016 - Wiley Online Library
Background Magnetic nanoparticles (MNPs) have been widely used in medical diagnostic
research. In this work, two technologies, MNPs and polymerase chain reaction (PCR), were …
research. In this work, two technologies, MNPs and polymerase chain reaction (PCR), were …
[HTML][HTML] Monitoramento de doença residual mínima em leucemia mielóide crônica por PCR em tempo real
PSR Almeida, VA Saddi - Revista Brasileira de Hematologia e …, 2007 - SciELO Brasil
O monitoramento de doença residual mínima (DRM) em leucemia mielóide crônica é
extremamente importante, pois possibilita o diagnóstico precoce de eventuais recidivas da …
extremamente importante, pois possibilita o diagnóstico precoce de eventuais recidivas da …
Targeted diagnostics and therapeutics for individualized patient management
S Waldman, A Terzic - 2007 - Future Medicine
Advances in deconvoluting complex disease processes, enabling genomic, proteomic,
metabolomic and imaging technologies, highthroughput drug discovery and development …
metabolomic and imaging technologies, highthroughput drug discovery and development …